FDA AdComm Votes In Favor Of GSK's Jemperli Single Arm Trial Plan For Rectal Cancer Setting

  • The FDA's Oncologic Drugs Advisory Committee backed GSK plc's GSK proposed single-arm trials to gain accelerated approval of its PD-1 inhibitor Jemperli in a rare subtype of locally advanced rectal cancer.
  • The Advisory Committee voted 8-5 to support GSK's proposal, which includes a single-arm trial of mismatch repair-deficient (MMR-deficient) or microsatellite instability-high (MSI-H) rectal cancer.
  • The proposed overall clinical development program will consist of two single-arm trials, including:
    • A single-center trial that will enroll 30 patients
    • A proposed multicenter trial that will enroll 100 patients. 
  • Related: FDA Grants Complete Approval For GSK's Jemperli For Endometrial Cancer.
  • GSK is initiating a global, open-label, phase 2 trial to investigate the efficacy and safety of dostarlimab-gxly as monotherapy – as a replacement for chemotherapy, radiation and/or surgery – for treatment-naïve patients with dMMR/MSI-H locally advanced rectal cancer. 
  • In September 2022, FDA and GSK held a Type B meeting.
  • The FDA expressed concerns regarding some elements of the proposed strategy to support accelerated approval and verify clinical benefits, including:
    • Adequacy of data derived from a small cohort of patients from two single-arm trials to support approval. 
    • The proposed and unprecedented use of cCR12 as an endpoint for accelerated approval.
    • Data package proposed to verify clinical benefit, including the role of a proposed study in patients with colon cancer. 
  • Price Action: GSK shares are down 1.19% at $36.00 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!